Open Access

The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia

  • Xiaofeng Guo1,
  • Zhanchou Zhang1,
  • Qinling Wei2,
  • Hailong Lv1,
  • Renrong Wu1 and
  • Jingping Zhao1Email author
BMC PsychiatryBMC series ¿ open, inclusive and trusted201313:109

DOI: 10.1186/1471-244X-13-109

Received: 24 November 2012

Accepted: 27 March 2013

Published: 9 April 2013

Abstract

Background

Studies have reported that up to 60% of individuals with schizophrenia are overweight or obese. This study explored the relationship between obesity and cognitive performance in Chinese patients with schizophrenia.

Methods

Outpatients with schizophrenia aged 18–50 years were recruited from 10 study sites across China. Demographic and clinical information was collected. A neuropsychological battery including tests of attention, processing speed, learning/memory, and executive functioning was used to assess cognitive function, and these 4 individual domains were transformed into a neurocognitive composite z score. In addition, height and weight were measured to calculate body mass index (BMI). Patients were categorized into 4 groups (underweight, normal weight, overweight and obese) based on BMI cutoff values for Asian populations recommended by the World Health Organization.

Results

A total number of 896 patients were enrolled into the study. Fifty-four percent of participants were overweight or obese. A higher BMI was significantly associated with lower scores on the Wechsler Memory Scale-Revised (WMS-R) Visual Reproduction subscale, the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol subscale, and the composite z score (p’s ≤ 0.024). Obese patients with schizophrenia had significantly lower scores than normal weight patients on the Trail Making Test B, the WMS-R Visual Reproduction subscale, the WAIS Digit Symbol subscale, and the composite z score (p’s ≤ 0.004).

Conclusions

Our study suggests that, in addition to its well established risk for various cardiometabolic conditions, obesity is also associated with decreased cognitive function in Chinese patients with schizophrenia. Future studies should explore if weight loss and management can improve cognitive function in obese patients who suffer from schizophrenia.

Keywords

Schizophrenia Cognitive function Body mass index Obesity Overweight

Background

Patients with schizophrenia suffer from moderate to severe cognitive impairment especially in the domains of attention, executive functioning, memory, verbal skills, and processing speed impairments [1, 2]. Cognitive deficits may represent a core pathophysiological feature of the illness, and these deficits have been found in first episode patients, as well as first-degree relatives of schizophrenia patients [3, 4].

Obesity is common in the schizophrenia population [5]. According to recent studies,40-60% of schizophrenia patients are overweight or obese [610]. Accumulating evidence indicates that obesity is associated with cognitive dysfunction in non-schizophrenia populations [1114]. A cross-sectional study of 2,223 healthy workers aged 32 to 62 years showed that body mass index (BMI) was independently associated with cognitive function (word-list learning and the Digit-symbol Substitution Test) [15]. Another study in patients with bipolar disorder suggested that overweight and obesity had a potential negative effect on cognitive function [16]. The cognitive domains most likely adversely affected by excess weight include learning, memory and executive function.

Previous studies in Asian populations have shown that Asians have higher amounts of body fat at lower BMIs than do Western populations, leading to a higher risk for poorer cognitive function in Asian people than in Western people with comparable BMIs [17]. Therefore, there might be differential relationships between obesity as measured by BMI and cognitive function across different racial or ethnic populations.

It has been well documented that overweight or obesity is associated with decreased self-esteem and quality of life, treatment noncompliance, and increased risk for medical comorbidity in schizophrenia [1820]. However, few previous studies have specifically examined the relationship between overweight or obesity and cognitive function in this patient population. The purpose of this study was to investigate how obesity might be associated with cognitive function in Chinese patients with schizophrenia.

Methods

Sample

This study was part of the Early-stage Schizophrenia Outcome Study (ESOS), which involved 10 different sites across China [20]. Study participants were enrolled from psychiatric outpatient clinics. The inclusion criteria were: (1) age range between 18 to 50 years old; (2) diagnosis of schizophrenia or schizophreniform disorder as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders–Clinician Version administered by study investigators or trained staff; (3) duration of illness ≤ 5 years; (4) in stable clinical condition (the Positive and Negative Syndrome Scale [PANSS][21]total scores ≤ 60); (5) on only one oral antipsychotic agent. The exclusion criteria were: (1) a history of neurologic disorders that might affect cognitive function (i.e. head injury, cerebrovascular disease, Parkinson’s disease, Alzheimer’s disease, seizure disorder), (2) serious or unstable medical condition (i.e. poorly controlled diabetes or hypertension, symptomatic coronary artery disease) or BMI ≥ 45 kg/m2; (3) current pregnancy or breastfeeding, or history of pregnancy in the past 12 months; (4) substance abuse or dependence in the past 3 months.

The study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board at the Second Xiangya Hospital, Chongqing Mental Health Center, Psychiatric Hospital of Jiangxi Province, West China Hospital, Mental Hospital of Henan Province, Beijing Anding Hospital, Shanghai Mental Health Center, Guangzhou Brain Hospital, Hunan Brain Hospital, and Nanjing Brain Hospital. A written informed consent was obtained from each subject, or his or her legal guardians.

Cognitive assessment

A cognitive battery was administered to all participants. The battery includes the following five cognitive tests:
  1. 1)

    the Wechsler Adult Intelligence Scale-Revised Digit Symbol Test [22]: this is a test of processing speed requiring the examinee to copy symbols that match the numbers 1 through 9 according to a key; the number of symbols completed correctly within 120 seconds was used as the performance measure.

     
  2. 2)

    Trail Making Test, Part A and B [23]: these tests measure processing speed and executive function, respectively. Part A requires the subject to draw lines connecting numbers in order; Part B requires the subject to alternate between numbers and letters. The time to complete each test was used as the performance measure.

     
  3. 3)

    The Wechsler Adult Intelligence Scale-Revised Digit Span Test [22]: this test measures attention and working memory and requires the subject to repeat increasingly long strings of digits forward, and then backward. The number of correctly recalled trials in each condition was used as the performance measure.

     
  4. 4)

    The computerized Wisconsin Card Sorting Test (WCST, 128-card version) [24]: this is a commonly used test for executive function, measuring abstraction and cognitive flexibility; the number of categories completed and the number of perseverative errors were used as the performance measures.

     
  5. 5)

    The Wechsler Memory Scale-Revised Visual Reproduction Test [25]: this is a visual learning and memory test requiring the subject to copy and recall abstract line drawings; the immediate recall raw score was used as the performance measure.

     

The eight performance measures were grouped into 4 domains including Processing Speed (Digit Symbol; Trail Making Test, Part A), Attention/Working Memory (Digit Span total), Executive Functioning (Trail Making Test, Part B; WCST perseverative errors and categories completed), and Visual Memory (Visual Reproduction).

All the tests were administered by raters with a masters degree in clinical psychology; an inter-rater reliability was established. The raters were blind to participants’ medical status at the time of assessment.

Clinical and BMI measurements

Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) [21] and the Montgomery and Asberg Depression Scale (MADRS) [26].

Height and weight were measured using the standardized procedures. BMI was calculated based on the formula: weight in kilograms divided by height in meters-squared (kg/m2). According to the World Health Organization Standard classification on body mass index for Asians [27], subjects were defined as underweight (< 18.5 kg/m2), normal weight (18.5-22.9 kg/m2), overweight (23–27.4 kg/m2) and obese (≥ 27.5 kg/m2).

Statistical analysis

All analyses were conducted using the Statistical Package for Social Sciences, version 15.0 (SPSS Inc, Chicago, Illinois). A cognitive composite score was derived based on the scores on the five cognitive tests. Raw scores were first converted to standardized z-scores with the mean of 0 and the standard deviation of 1. For domains with more than one test, a domain z-score was created by calculating the mean of the z-scores for the measures comprising the domain, then converting the mean to a z score with a mean of zero and a standard deviation of 1. A cognitive composite score was calculated by creating a z score of the average of the 4 standardized domain scores.

Demographic and clinical characteristics across different BMI groups were compared using analysis of variance (ANOVA) for continuous variables and Chi-square tests for categorical variables. Group comparisons of cognitive function were performed using analysis of covariance (ANCOVA) controlling for gender. If an overall group difference was found to be significant, post hoc comparisons were then evaluated using the Hochberg modification of the Bonferroni correction for multiple comparisons: the adjusted alpha for statistical significance was calculated as α* = α/[k (k-1)/2] =0.05/[4*(4–1)/2] = 0.008 [28]. The correlations between BMI and cognitive function measures were performed using partial correlation tests controlling for both age and gender.

Results

Characteristics of the sample

A total of 896 patients completed the study and were included in the data analysis. The prevalence of obesity, overweight, and underweight were 18.1%, 35.6% and 6.4% respectively.

As shown in Table 1, there were no significant differences across different BMI groups (obesity, overweight, normal weight and underweight) on various demographic or clinical characteristics (p’s > 0.05) except for gender (p < 0.001).
Table 1

Demographic and clinical characteristics of the study sample a

Characteristic

Underweight (n = 57)

Normal weight (n = 358)

Overweight (n = 319)

Obese (n = 162)

F/χ2

p value

Age (years)

27.6 ± 8.5

27.1 ± 7.6

27.8 ± 6.6

27.8 ± 7.6

0.738

0.529

Male, N (%)

22(38.6)

162(45.3)

203(63.6)

106(65.4)

36.683

<0.001b

Marital Status, N (%)

    

3.931

0.686

 Married

37(64.9)

243(67.9)

197(61.8)

106(65.4)

  

 Never married

16(28.1)

94(26.3)

103(32.3)

49(30.2)

  

 Widowed, divorced, or separated

4(7.0)

21(5.9)

19(6.0)

7(4.3)

  

Education (years)

12.6 ± 2.8

12.5 ± 3.0

12.4 ± 2.9

12.9 ± 2.8

1.264

0.286

Occupation, N (%)

    

6.301

0.098

 Office worker

20(35.1)

159(44.4)

113(35.4)

66(40.7)

  

 Manual worker

37(64.9)

199(55.6)

206(64.6)

96(59.3)

  

Smoking cigarettes, N (%)

9(15.8)

53(17.4)

61(19.1)

31(19.1)

3.423

0.330

FBS (mg/dl)

88.8 ± 12.7

89.1 ± 12.0

89.3 ± 11.1

92.0 ± 18.8

0.809

0.489

SBP (kPa)

15.1 ± 1.0

14.9 ± 1.2

15.0 ± 1.2

15.2 ± 1.2

2.119

0.096

DBP (kPa)

9.9 ± 1.0

9.8 ± 0.8

9.9 ± 0.8

10.0 ± 0.8

1.996

0.113

DSM-IV diagnosis, N (%)

    

2.251

0.522

 Schizophrenia

52(91.2)

300(83.8)

273(85.6)

137(84.6)

  

 Schizophreniform disorder

5(8.8)

58(16.2)

46(14.4)

25(15.4)

  

Duration of illness (years)

2.2 ± 1.8

2.0 ± 1.7

2.1 ± 1.8

2.4 ± 1.8

1.706

0.164

PANSS total score

47.6 ± 16.5

44.8 ± 14.6

44.8 ± 14.6

46.0 ± 12.9

1.325

0.265

MADRS total score

5.0 ± 5.5

5.2 ± 5.7

5.1 ± 5.5

5.3 ± 5.5

0.106

0.956

Current medication, N (%)

    

7.063

0.070

 Typical antipsychotics

21(31.6)

109(30.4)

71(22.3)

39(24.1)

  

 Atypical antipsychotics

36(68.4)

249(69.6)

248(77.7)

123(75.9)

  

Mean daily doses of medication (clorpromazine quivalent, mg/d)

315.7 ± 107.3

320.8 ± 104.4

322.0 ± 113.0

331.3 ± 115.5

0.447

0.719

Body mass index (kg/m2)

16.5 ± 2.4

21.1 ± 1.9

24.9 ± 1.3

29.6 ± 2.4

2203.838

<0.001

aAsian BMI categories(kg/m2): underweight (< 18.5), normal weight(18.5-22.9), overweight (23–27.4) and obese (≥ 27.5); Data are presented as mean ± SD unless otherwise indicated. Percentages may not sum up to 100 because of rounding.

b underweight vs overweight, p < 0.001; underweight vs obese, p < 0.001; normal weight vs overweight, p < 0.001; normal weight vs obese, p < 0.001;

Abbreviation: FBS, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; PANSS, the Positive and Negative Syndrome Scale; MADRS, Montgomery-Asberg Depression Scale.

Correlations between BMI and cognitive measures

Correlations between BMI and various cognitive measures are showed in Table 2. Partial correlation analysis adjusting for gender demonstrated that a higher BMI was significantly associated with lower scores on the WAIS-R Digit Symbol test, the WMS-R Visual Reproduction test, and the composite z score (p’s ≤ 0.024).
Table 2

Partial correlations between body mass index and cognitive function measures controlling for both age and gender

Characteristic

Body mass index

p value

WAIS-R Digit Symbol

−0.076

0.023

Trail Making Test A

0.016

0.641

Trail Making Test B

0.023

0.493

WCST Perseverative Errors

0.005

0.877

WCST Categories Completed

−0.027

0.420

WAIS-R Digit Span

−0.031

0.362

WMS-R Visual Reproduction

−0.131

<0.001

Composite z score

−0.082

0.018

Abbreviation: WAIS, Wechsler Adult Intelligence Scale-Revised; WCST, Computerized Wisconsin Card Sorting Test; WMS-R, Wechsler Memory Scale-Revised; BMI, Body mass index.

Comparison of cognitive measures across different BMI groups

There were significant overall group differences in the Trail Making Test B, the WMS-R Visual Reproduction test, the WAIS Digit Symbol test, and the composite z score (p’s ≤ 0.040; Table 3). Post hoc analysis revealed that the obese group had significantly lower scores on the Trail Making Test B, the WMS-R Visual Reproduction test, the WAIS Digit Symbol test, and the composite z score compared with the normal weight group (p’s ≤ 0.004).
Table 3

Comparisons of cognitive function measures across different BMI groups a

Characteristic

Underweight (n = 57)

Normal weight (n = 358)

Overweight (n = 319)

Obese (n = 162)

F

p value

WAIS-R Digit Symbol

47.5 ± 15.8

48.3 ± 14.1

46.6 ± 12.8

44.0 ± 13.2

3.922

0.009b

Trail Making Test A

56.6 ± 23.7

52.5 ± 24.3

54.9 ± 29.5

55.6 ± 27.3

0.842

0.471

Trail Making Test B

112.3 ± 59.0

106.7 ± 54.6

114.4 ± 61.4

123.7 ± 55.5

2.784

0.040c

WCST Perseverative Errors

40.4 ± 25.8

42.7 ± 24.7

42.9 ± 23.7

41.6 ± 26.5

0.241

0.868

WCST Categories Completed

2.7 ± 2.2

2.5 ± 2.1

2.6 ± 2.1

2.8 ± 2.2

0.491

0.688

WAIS-R Digit Span

12.0 ± 3.8

12.5 ± 3.5

12.3 ± 3.1

11.9 ± 3.0

1.606

0.186

WMS-R Visual Reproduction

8.9 ± 2.8

9.3 ± 3.0

8.6 ± 2.9

8.2 ± 3.5

5.921

0.001d

Composite z score

0.10 ± 0.09

0.20 ± 0.03

0.10 ± 0.03

0.01 ± 0.05

4.365

0.005e

a Asian BMI categories(kg/m2): underweight (< 18.5), normal weight(18.5-22.9), overweight (23–27.4) and obese (≥ 27.5); Data are presented as mean ± SD.

bnormal weight vs obese, P = 0.001; cnormal weight vs obese, P = 0.004; dnormal weight vs obese, P = 0.001;normal weight vs overweight, P = 0.012 e normal weight vs obese, P = 0.004;

Abbreviation: WAIS, Wechsler Adult Intelligence Scale-Revised; WCST, Computerized Wisconsin Card Sorting Test; WMS-R, Wechsler Memory Scale-Revised; BMI, Body mass index.

Gender, obesity, and cognitive measures

There was a significant difference in BMI between males and females (24.1 ± 3.7 and 22.8 ± 3.1, respectively, F = 29.872, p < 0.001). However, there were no significant differences in various cognitive measures between the two gender groups (p’s > 0.05; data not shown). Further analysis within each gender group showed that the obese group had significantly lower scores on the WMS-R Visual Reproduction test, the WAIS Digit Symbol test, and the composite z score compared with the normal weight group (p’s ≤ 0.004; data not shown).

Antipsychotic agents, obesity and cognitive measures

There was a significant difference in BMI between patients on typical antipsychotics and those on atypical antipsychotics (22.9 ± 3.5 and 23.6 ± 3.5, respectively, F = 10.909, p = 0.001), but there were no significant differences in various cognitive measures between those taking typical vs. atypical antipsychotics (p’s >0.05; data not shown).

Discussion

In this study, the percentage of overweight or obese Chinese patients with schizophrenia was 54%, which is higher than in the general Chinese population (43.1%) [29]. Moreover, we found that obese patients with schizophrenia demonstrated poorer cognitive performance than the normal weight patients. To our knowledge, this is the largest study to assess the relationship between obesity and cognitive function in schizophrenia. The findings of this study suggested that obesity, in addition to being a risk factor for various medical conditions, is associated with decreased cognitive function in patients with schizophrenia.

The exact mechanisms linking obesity and cognitive dysfunction remain unclear. Obesity is associated with vascular changes, impaired insulin regulation, and reduced cardiovascular fitness, which all might contribute to decreased cognitive function [3032]. In addition, nonvascular mechanisms linking obesity with cognitive impairment have also been suggested [33]. Leptin, an adipocyte-secreted protein related to obesity, may play a role in learning and memory [34]. Interestingly, higher levels of serum leptin appear to protect against cognitive decline in elderly individuals, suggesting leptin resistance as a causal pathway from obesity to cognitive impairment [35]. It is also possible that schizophrenia patients with cognitive impairment are more likely to become obese [12]. If so, much additional work is needed to clarify the association between BMI and worse cognitive performance.

In our study, a higher BMI was found in patients treated with atypical antipsychotics than in those treated with typical agents. However, there was no significant difference in cognitive function between patients on typical vs. atypical antipsychotics. Some atypical antipsychotic agents are associated with significant metabolic side effects; typical antipsychotic agents are more likely to cause other side effects such as extrapyramidal symptoms [36]. This may be the reason why previous studies showed atypical antipsychotic agents are associated with better cognitive function than typical agents in patients with schizophrenia [37].

Limitations

There are several limitations to this study. First, a more comprehensive cognitive battery might have revealed different results. Second, the participants were not randomly selected and the study excluded patients with serious or unstable medical conditions; as a result, the study sample may not be representative of individuals with schizophrenia in China. Third, given the cross-sectional study design, causal relationships cannot be drawn based on our findings. Fourth, BMI may not be the most appropriate measure to reflect obesity and its negative impact on cardiometabolic disorders and other health conditions [38]. Future studies using more sophisticated techniques, such as dual-energy X-ray absorptiometry, to measure body composition and percentage of fat are needed.

Conclusion

Our study suggests that, in addition to its well established risk for various cardiometabolic conditions, obesity is also associated with worse cognitive function in Chinese patients with schizophrenia. Future studies should explore if weight loss and management can improve cognitive function in obese patients who suffer from schizophrenia.

Abbreviations

BMI: 

Body mass index

WMS-R: 

The wechsler memory scale-revised

WAIS-R: 

The wechsler adult intelligence scale-revised

PANSS: 

Positive and negative syndrome scale

WCST: 

Wisconsin card sorting test

MADRS: 

Montgomery and asberg depression scale.

Declarations

Acknowledgements

We wish to thank all the investigators of Early-stage Schizophrenia Outcome Study (ESOS) who enrolled patients and collected data: Dr. B. Wang, Dr. B. Hu, Dr. X. Sun, Dr. L. Lv, Dr. C. Wang, Dr. Z. Lu, Dr. C. Ma, Dr. T. Guo, and Dr. S. Xie. We are also very grateful to X. Fan from Massachusetts General Hospital, Harvard Medical School and E. W. Twamley from Department of Psychiatry, University of California for assistance in revising our manuscript.

This study was supported by the National Key Technologies R&D Program in the 10th 5-year-plan of China (Grant No. 2004BA720A22); the National Natural Science Foundation of China (Grant No. 30900485 and 81270019); and the National R&D Special Fund for Health Profession (Grant No. 201002003).

Authors’ Affiliations

(1)
Institute of Mental Health, the Second Xiangya Hospital, Central South University
(2)
Department of Psychiatry, 3rd Affiliated Hospital of Sun Yat-sen University

References

  1. Green MF, Kern RS, Braff DL, Mintz J: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr Bull. 2000, 26 (1): 119-136. 10.1093/oxfordjournals.schbul.a033430.View ArticlePubMed
  2. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG: Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry. 2007, 64 (10): 1115-1122. 10.1001/archpsyc.64.10.1115.View ArticlePubMed
  3. Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA: Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr Res. 2004, 68 (1): 49-63. 10.1016/S0920-9964(03)00213-5.View ArticlePubMed
  4. Snitz BE, Macdonald AR, Carter CS: Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006, 32 (1): 179-194.PubMed CentralView ArticlePubMed
  5. Susce MT, Villanueva N, Diaz FJ, de Leon J: Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry. 2005, 66 (2): 167-173. 10.4088/JCP.v66n0203.View ArticlePubMed
  6. Coodin S: Body mass index in persons with schizophrenia. Can J Psychiatry. 2001, 46 (6): 549-555.PubMed
  7. Catapano L, Castle D: Obesity in schizophrenia: what can be done about it?. Australas Psychiatry. 2004, 12 (1): 23-25. 10.1046/j.1039-8562.2003.02054.x.View ArticlePubMed
  8. Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N: Psychiatric medication-induced obesity: a review. Obes Rev. 2004, 5 (2): 115-121. 10.1111/j.1467-789X.2004.00139.x.View ArticlePubMed
  9. Tardieu S, Micallef J, Gentile S, Blin O: Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev. 2003, 4 (3): 129-138. 10.1046/j.1467-789X.2003.00105.x.View ArticlePubMed
  10. Muller DJ, Muglia P, Fortune T, Kennedy JL: Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res. 2004, 49 (4): 309-329. 10.1016/j.phrs.2003.05.001.View ArticlePubMed
  11. Taki Y, Kinomura S, Sato K, Inoue K, Goto R, Okada K, Uchida S, Kawashima R, Fukuda H: Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring). 2008, 16 (1): 119-124. 10.1038/oby.2007.4.View Article
  12. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E: Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry. 2007, 48 (1): 57-61. 10.1016/j.comppsych.2006.05.001.View ArticlePubMed
  13. Gunstad J, Spitznagel MB, Paul RH, Cohen RA, Kohn M, Luyster FS, Clark R, Williams LM, Gordon E: Body mass index and neuropsychological function in healthy children and adolescents. Appetite. 2008, 50 (2–3): 246-251.View ArticlePubMed
  14. Gunstad J, Lhotsky A, Wendell CR, Ferrucci L, Zonderman AB: Longitudinal examination of obesity and cognitive function: results from the Baltimore longitudinal study of aging. Neuroepidemiology. 2010, 34 (4): 222-229. 10.1159/000297742.PubMed CentralView ArticlePubMed
  15. Cournot M, Marquie JC, Ansiau D, Martinaud C, Fonds H, Ferrieres J, Ruidavets JB: Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology. 2006, 67 (7): 1208-1214. 10.1212/01.wnl.0000238082.13860.50.View ArticlePubMed
  16. Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, McIntyre RS: The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry. 2012, 27 (3): 223-228. 10.1016/j.eurpsy.2011.02.004.View ArticlePubMed
  17. Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC: Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand. 2013, 127 (3): 217-226. 10.1111/acps.12009.PubMed CentralView ArticlePubMed
  18. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353 (12): 1209-1223. 10.1056/NEJMoa051688.View ArticlePubMed
  19. Saddichha S, Vishnuvardhan G, Akhtar S: Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia. Int J Risk Saf Med. 2011, 23 (3): 181-185.PubMed
  20. Guo X, Zhai J, Liu Z, Fang M, Wang B, Wang C, Hu B, Sun X, Lv L, Lu Z: Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry. 2010, 67 (9): 895-904. 10.1001/archgenpsychiatry.2010.105.PubMed CentralView ArticlePubMed
  21. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276. 10.1093/schbul/13.2.261.View ArticlePubMed
  22. Wechsler D: The wechsler adult intelligence scale-revised. 1981, New York: Psychological Corp
  23. Reitan RM, Wolfson D: The halstead-reitan neuropsychological test battery: theory and clinical interpretation. 1993, South Tucson, AriZ: Neuropsychology Press, 2
  24. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtis G: Wisconsin card sorting test manual. 1993, Odessa, Fla: Psychological Assessment Resources
  25. Wechsler D: The wechsler memory scale-revised. 1987, San Antonio, Tex: Psychological Corp
  26. Davidson J, Turnbull CD, Strickland R, Miller R, Graves K: The montgomery-asberg depression scale: reliability and validity. Acta Psychiatr Scand. 1986, 73 (5): 544-548. 10.1111/j.1600-0447.1986.tb02723.x.View ArticlePubMed
  27. WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004, 363 (9403): 157-163.View Article
  28. Howell DC: Statistical methods for psychology. 2009, Australia, Wadsworth: Cengage Learning, 7
  29. Wang R, Wu MJ, Ma XQ, Zhao YF, Yan XY, Gao QB, He J: Body mass index and health-related quality of life in adults: a population based study in five cities of China. Eur J Public Health. 2012, 22 (4): 497-502. 10.1093/eurpub/ckr080.View ArticlePubMed
  30. Convit A, Wolf OT, Tarshish C, de Leon MJ: Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci U S A. 2003, 100 (4): 2019-2022. 10.1073/pnas.0336073100.PubMed CentralView ArticlePubMed
  31. Rahmouni K, Correia ML, Haynes WG, Mark AL: Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005, 45 (1): 9-14.View ArticlePubMed
  32. Ylikoski R, Ylikoski A, Raininko R, Keskivaara P, Sulkava R, Tilvis R, Erkinjuntti T: Cardiovascular diseases, health status, brain imaging findings and neuropsychological functioning in neurologically healthy elderly individuals. Arch Gerontol Geriatr. 2000, 30 (2): 115-130. 10.1016/S0167-4943(00)00045-5.View ArticlePubMed
  33. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L: The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry. 2010, 167 (10): 1232-1239. 10.1176/appi.ajp.2010.09091328.View ArticlePubMed
  34. Funahashi H, Yada T, Suzuki R, Shioda S: Distribution, function, and properties of leptin receptors in the brain. Int Rev Cytol. 2003, 224: 1-27.View ArticlePubMed
  35. Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K: Serum leptin level and cognition in the elderly: findings from the health ABC study. Neurobiol Aging. 2009, 30 (9): 1483-1489. 10.1016/j.neurobiolaging.2007.11.024.View ArticlePubMed
  36. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009, 373 (9657): 31-41. 10.1016/S0140-6736(08)61764-X.View ArticlePubMed
  37. Hill SK, Bishop JR, Palumbo D, Sweeney JA: Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010, 10 (1): 43-57. 10.1586/ern.09.143.PubMed CentralView ArticlePubMed
  38. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F: Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006, 368 (9536): 666-678. 10.1016/S0140-6736(06)69251-9.View ArticlePubMed
  39. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-244X/​13/​109/​prepub

Copyright

© Guo et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement